BiochemistrybioRxiv
Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2
R. K. Singh, A. Soliman, G. Guaitoli…·W. Versees
This study identifies and characterizes Nanobodies that modulate LRRK2 activity through non-ATP-competitive mechanisms, offering new tools for Parkinson's disease research and therapy.
DOI 10.1073/pnas.2112712119